Moderna, Inc. Common Stock (MRNA) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was author...
Moderna, Inc. Common Stock (MRNA) currently trades at a P/E ratio of 32.78 (historical range: 3.41–55.93, median: 8.64), placing it at the 88th percentile — expensive relative to its history, P/S ratio of 39.07 (range: 2.17–42.38, 100th percentile — expensive relative to its history).
Moderna, Inc. Common Stock trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 32.78 | 8.64 | 88th | expensive relative to its history |
| P/S Ratio | 39.07 | 4.12 | 100th | expensive relative to its history |
| FCF Yield | 1.24% | 10.57% | 12th | expensive relative to its history |
Moderna, Inc. Common Stock (MRNA) Valuation & P/E History
Moderna, Inc. Common Stock (MRNA) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry currently trading at $215.69 with a market capitalization of $86.1 billion. This page provides historical valuation analysis for MRNA based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 32.78 is above the historical median of 8.64, placing MRNA at the 88th percentile of its valuation range. The P/S ratio of 39.07 compares to a median of 4.12.
MRNA Valuation Metrics & Historical Range
The valuation table above shows Moderna, Inc. Common Stock's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether MRNA is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests MRNA is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Moderna, Inc. Common Stock.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is MRNA Overvalued or Undervalued?
Moderna, Inc. Common Stock trades well above its own historical valuation range across most metrics. The overall valuation percentile of 94 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive MRNA is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full MRNA analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.MRNA trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.